This suggests that CYP2C9 gene polymorphisms contribute to distinct CYP2C9 enzyme activities and metabolic capabilities towards rosuvastatin, consequently influencing the lipid-lowering effect of rosuvastatin in patients with hypercholesterolemia (Lin et al., 2015), which serves as a reminder that the activities of drug-metabolizing enzymes in patients themselves exert a certain influence on the lipid-lowering efficacy of statins. Here, CYP2C9 is linked to Hypercholesterolemia.